Jpm Free Full Text Targeted Treatment Of Follicular Lymphoma Follicular lymphoma (fl) is the most common indolent b cell lymphoma. advanced stage disease is considered incurable and is characterized by a prolonged relapsing remitting course. a significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. recent advances in our understanding of the unique genetic and immune biology of fl have led to. Background: the treatment of follicular lymphoma (fl) has previously centered on chemoimmunotherapy, which can be disadvantageous due to patient intolerance, cumulative toxicities, and disease refractoriness. targeted therapies can produce deep responses and improve progression free and overall survival with more tolerable adverse event profiles. methods: we summarize the current literature.
Jpm Free Full Text Targeted Treatment Of Follicular Lymphoma Go to: 1. introduction. follicular lymphoma (fl) is the second most common type of non hodgkin lymphoma (nhl) in western countries [ 1 ]. it is characterized by a waxing and waning disease course where patients can experience multiple relapses between disease free periods. although patients with prolonged responses have excellent outcomes. Follicular lymphoma (fl) is the most common indolent b cell lymphoma. advanced stage disease is considered incurable and is characterized by a prolonged relapsing remitting course. a significant minority have less favorable outcomes, particularly those with transformed or early progressive disease. recent advances in our understanding of the. Follicular lymphoma (fl) is the most common indolent b cell lymphoma. advanced stage disease is considered incurable and is characterized by a prolonged relapsing remitting course. Background: the treatment of follicular lymphoma (fl) has previously centered on chemoimmunotherapy, which can be disadvantageous due to patient intolerance, cumulative toxicities, and disease refractoriness. targeted therapies can produce deep responses and improve progression free and overall survival with more tolerable adverse event profiles.
Comments are closed.